Please try another search
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Name | Age | Since | Title |
---|---|---|---|
Oleg Michael Pohotsky | 77 | 2000 | Chairman |
Lucinda H. Stebbins | 79 | 2006 | Independent Trustee |
Uwe E. Reinhardt | 87 | 1992 | Independent Trustee |
William S. Reardon | 78 | 2010 | Trustee |
Rakesh K. Jain | 74 | 2007 | Trustee |
Daniel R. Omstead | 71 | 2001 | Principal Executive Officer, President and Trustee |
Michael W. Bonney | 66 | 2011 | Trustee |
Rose F. DiMartino | 72 | - | Trustee |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review